Voleon Capital Management LP Has $9.38 Million Stock Position in Zoetis Inc. $ZTS

Key Points

• Voleon Capital Management LP increased its stake in Zoetis Inc. by 255.7%, owning 56,975 shares valued at approximately $9.38 million, making it the 28th largest holding in its portfolio.
• Zoetis reported a quarterly earnings per share of $1.76, exceeding estimates, with revenue of $2.46 billion reflecting a 4.2% year-over-year increase.
• Analyst ratings are mixed, with four analysts giving a Buy rating and four a Hold rating, leading to a consensus rating of "Moderate Buy" and a price target of $202.43.

Voleon Capital Management LP grew its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 255.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 56,975 shares of the company's stock after acquiring an additional 40,959 shares during the quarter. Zoetis accounts for approximately 0.7% of Voleon Capital Management LP's investment portfolio, making the stock its 28th biggest position. Voleon Capital Management LP's holdings in Zoetis were worth $9,381,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. 1248 Management LLC bought a new stake in Zoetis in the 1st quarter valued at about $27,000. Saudi Central Bank acquired a new stake in Zoetis during the first quarter worth approximately $29,000. Cornerstone Planning Group LLC increased its stake in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after acquiring an additional 88 shares during the period. Migdal Insurance & Financial Holdings Ltd. raised its holdings in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after acquiring an additional 120 shares in the last quarter. Finally, Sound Income Strategies LLC lifted its position in shares of Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after acquiring an additional 164 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

Shares of Zoetis stock traded up $1.24 during midday trading on Thursday, hitting $150.66. 3,193,921 shares of the company traded hands, compared to its average volume of 3,037,636. The firm's fifty day moving average price is $152.70 and its 200-day moving average price is $157.56. The stock has a market cap of $66.77 billion, a price-to-earnings ratio of 25.93, a PEG ratio of 2.40 and a beta of 0.89. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the business posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on ZTS shares. Argus restated a "buy" rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler upped their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and cut their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Zoetis has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.